Lilly To Acquire AtaiBeckley For $6.75 Per Share In Cash Plus Up To $2.50 Per Share In A Contingent Value Right Dependent Upon Milestones Related To The BPL-003 And VLS-01 Programs; Deal Valued At Up To ~$3.8B

President Trump Say In A Social Media Post That The University Of Miami Shared Its 1994 Ibogaine Investigational New Drug Application With The Government, Which Will Help Accelerate Development As A Medical Treatment In The U.S.

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.

CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday

Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.

Deutsche Bank Downgrades AtaiBeckley to Hold, Lowers Price Target to $8

Deutsche Bank analyst David Hoang downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold and lowers the price target from $12 to $8.

Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs

New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.

Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week

Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.